On this page:
- Copyright & trademarks
- Applicable laws
- Health information
- Forward-looking statements
Copyrights & trademarks
All content and images used on this site are owned or licensed by Baxter International Inc. or its affiliates ("Baxter") for use on this site only. Unauthorized use is prohibited.
Names of Baxter products and services are trademarks of Baxter International Inc. or its subsidiaries.
Nothing contained herein shall be construed as conferring any license or right under any Baxter patent, copyright, or trademark.
This site contains information concerning Baxter and its affiliates that may be useful to Baxter’s customers, suppliers, employees, and shareholders, as well as members of the general public. However, by using this site you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this website.
While reasonable efforts are made to ensure that the contents of this site are accurate, this site and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the site will be kept up to date, be true and not misleading, or that the site will always (or ever) be available for use. Baxter and its affiliates disclaim all warranties, express or implied, with respect to the site and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.
Baxter does not warrant that the servers that make this site available will be error-, virus-, worm-, or bug-free and you accept that it is your responsibility to make adequate provision for protection against such threats.
In no event will Baxter or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings,or business relationships, whether or not Baxter or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this site or its contents or any other sites linked to this site.
Baxter websites contain information about products that may or may not be available in any particular country, and if applicable, may have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations, and medical practices governing the communication of medical or other information about medical products on the Internet. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not authorized by the laws and regulations of the country where the reader resides.
This site may contain information on medical and health-related topics. This information is not meant to be a substitute for the advice provided by your own physician or other medical professional. You should not use this information for diagnosing a health problem or disease but should always consult your own physician.
The matters discussed on this website that are not historical facts include forward-looking statements concerning the company’s financial results, business development activities, capital structure, cost savings initiatives, R&D pipeline including results of clinical trials and planned product launches, and outlook for 2017 (including estimates regarding the proposed impact of Hurricane Maria on the company’s fourth quarter operations). The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products, and the impact of those products on quality or patient safety concerns; product development risks; product quality or patient safety concerns; future actions of regulatory bodies and other governmental authorities, including FDA, the Department of Justice, the New York Attorney General and foreign regulatory agencies (including with respect to the granting of temporary importation approvals); failures with respect to compliance programs; future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; global, trade and tax policies; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisition of Claris Injectables in July 2017); fluctuations in supply and demand (including as a result of a natural disaster or otherwise); the availability of acceptable raw materials and component supply; the inability to create timely production capacity or other manufacturing supply difficulties; the ability to achieve the intended results associated with the separation of the biopharmaceutical and medical products businesses; the ability to enforce owned or in-licensed patents or the patents of third parties preventing or restricting manufacture, sale or use of affected products or technology; the impact of global economic conditions; fluctuations in foreign exchange and interest rates; any change in law concerning the taxation of income, including income earned outside the United States; actions taken by tax authorities in connection with ongoing tax audits; breaches or failures of the company’s information technology systems; loss of key employees or inability to identify and recruit new employees; the outcome of pending or future litigation; the adequacy of the company’s cash flows from operations to meet its ongoing cash obligations and fund its investment program; and other risks identified in Baxter’s most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.